# Porokeratosis of Mibelli Treated With Topical 2% Lovastatin/2% Cholesterol Ointment

## TL;DR

A 56-year-old man with a long-lasting skin condition called porokeratosis of Mibelli showed significant improvement after using a new topical treatment containing lovastatin and cholesterol.

## Contribution

The study introduces a novel topical treatment combining 2% lovastatin and 2% cholesterol for porokeratosis of Mibelli.

## Key findings

- The patient showed significant clinical improvement after nine months of treatment.
- The lesion was markedly reduced in size and appearance.
- The treatment proved effective where previous therapies had failed.

## Abstract

Porokeratosis is characterized by disruptions in the isoprenoid pathway, leading to the development of cornoid lamella, a unique skin lesion consisting of parakeratotic cells. The condition has a genetic foundation involving mutations affecting cholesterol synthesis, and new treatments aim to address these metabolic disruptions. This study examines a 56-year-old male with porokeratosis of Mibelli (PM) who presented with a non-healing erosion on his finger that persisted for two years. Previous therapies, including corticosteroids, antibiotics, and tacrolimus, proved ineffective. The patient then received a novel treatment with a topical 2% lovastatin/2% cholesterol ointment. After nine months, there was significant clinical improvement; the lesion was markedly reduced in size and appearance. This case underscores the potential of lovastatin/cholesterol ointment as an effective treatment for PM, indicating its promise for broader therapeutic applications.